Page 1989 - Williams Hematology ( PDFDrive )

1964 Part XII: Hemostasis and Thrombosis Chapter 114: Control of Coagulation Reactions 1965

189. Griffin JH, Kojima K, Banka CL, et al: High-density lipoprotein enhancement of anticoag- 218. Deguchi H, Yegneswaran S, Griffin JH: Sphingolipids as bioactive regulators of
ulant activities of plasma protein S and activated protein C. J Clin Invest 103(2):219–227, thrombin generation. J Biol Chem 279(13):12036–12042, 2004.
1999. 219. Esmon CT: Interactions between the innate immune and blood coagulation systems.
190. Fernandez JA, Deguchi H, Banka CL, et al: Re-evaluation of the anticoagulant proper- Trends Immunol 25(10):536–542, 2004.
ties of high-density lipoprotein. Arterioscler Thromb Vasc Biol 35(3):570–572, 2015. 220. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and
191. Curvers J, Thomassen MC, Nicolaes GAF, et al: Acquired APC resistance and oral coagulation. Circulation 109(22):2698–2704, 2004.
contraceptives: Differences between two functional tests. Br J Haematol 105(1):88–94, 221. Riewald M, Ruf W: Protease-activated receptor-1 signaling by activated protein C in
1999. cytokine perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem
192. Smirnov MD, Safa O, Esmon NL, Esmon CT: Inhibition of activated protein C antico- 280(20):19808–19814, 2005.
agulant activity by prothrombin. Blood 94(11):3839–3846, 1999. 222. Kerschen EJ, Hernandez I, Zogg M, et al: Activated protein C targets CD8+ dendritic cells
193. Brugge JM, Tans G, Rosing J, Castoldi E: Protein S levels modulate the activated pro- to reduce the mortality of endotoxemia in mice. J Clin Invest 120(9):3167–3178, 2010.
tein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 223. Guo H, Zhao Z, Yang Q, et al: An activated protein C analog stimulates neuronal
95(2):236–242, 2006. production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.
194. Bakker HM, Tans G, Janssen-Claessen T, et al: The effect of phospholipids, calcium ions J Neurosci 33(14):6181–6190, 2013.
and protein S on rate constants of human factor Va inactivation by activated human 224. Xue M, Chow SO, Dervish S, et al: Activated protein C enhances human keratinocyte
protein C. Eur J Biochem 208(1):171–178, 1992. barrier integrity via sequential activation of epidermal growth factor receptor and tie2.
195. Smirnov MD, Esmon CT: Phosphatidylethanolamine incorporation into vesicles J Biol Chem 286(8):6742–6750, 2011.
selectively enhances factor Va inactivation by activated protein C. J Biol Chem 269(2): 225. Riewald M, Petrovan RJ, Donner A, et al: Activation of endothelial cell protease acti-
816–819, 1994. vated receptor 1 by the protein C pathway. Science 296(5574):1880–1882, 2002.
196. Smirnov MD, Triplett DT, Comp PC, et al: On the role of phosphatidylethanolamine 226. Mosnier LO, Zlokovic BV, Griffin JH: Cytoprotective-selective activated protein C ther-
in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin apy for ischaemic stroke. Thromb Haemost 112(5):883–892, 2014.
Invest 95(1):309–316, 1995. 227. Zlokovic BV, Griffin JH: Cytoprotective protein C pathways and implications for stroke
197. Fernández JA, Kojima K, Petäjä J, et al: Cardiolipin enhances protein C pathway antico- and neurological disorders. Trends Neurosci 34(4):198–209, 2011.
agulant activity. Blood Cells Mol Dis 26(2):115–123, 2000. 228. Wildhagen KC, Lutgens E, Loubele ST, et al: The structure-function relationship of
198. Rezende SM, Simmonds RE, Lane DA: Coagulation, inflammation, and apoptosis: activated protein C. Lessons from natural and engineered mutations. Thromb Haemost
Different roles for protein S and the protein S-C4b binding protein complex. Blood 106(6):1034–1045, 2011.
103(4):1192–1201, 2004. 229. Kerschen EJ, Fernandez JA, Cooley BC, et al: Endotoxemia and sepsis mortality reduc-
199. Yegneswaran S, Smirnov MD, Safa O, et al: Relocating the active site of activated protein tion by non-anticoagulant activated protein C. J Exp Med 204(10):2439–2448, 2007.
C eliminates the need for its protein S cofactor. A fluorescence resonance energy trans- 230. Wang Y, Sinha RK, Mosnier LO, et al: Neurotoxicity of the anticoagulant-selective
fer study. J Biol Chem 274(9):5462–5468, 1999. E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells Mol
200. Yegneswaran S, Wood GM, Esmon CT, Johnson AE: Protein S alters the active site Dis 51(2):104–108, 2013.
location of activated protein C above the membrane surface. A fluorescence resonance 231. Guo H, Singh I, Wang Y, et al: Neuroprotective activities of activated protein C mutant
energy transfer study of topography. J Biol Chem 272(40):25013–25021, 1997. with reduced anticoagulant activity. Eur J Neurosci 29(6):1119–1130, 2009.
201. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN: Inactivation of human factor VIII by 232. Wang Y, Thiyagarajan M, Chow N, et al: Differential neuroprotection and risk for
activated protein C. Cofactor activity of protein S and protective effect of von Wille- bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke
brand factor. J Clin Invest 82(4):1236–1243, 1988. 40(5):1864–1869, 2008.
202. Solymoss S, Tucker MM, Tracy PB: Kinetics of inactivation of membrane-bound fac- 233. Cheng T, Liu D, Griffin JH, et al: Activated protein C blocks p53-mediated apoptosis in
tor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem ischemic human brain endothelium and is neuroprotective. Nat Med 9(3):338–342, 2003.
263(29):14884–14890, 1988. 234. Cheng T, Petraglia AL, Li Z, et al: Activated protein C inhibits tissue plasminogen acti-
203. Dahlbäck B, Hildebrand B, Malm J: Characterization of functionally important vator-induced brain hemorrhage. Nat Med 12(11):1278–1285, 2006.
domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol 235. Griffin JH, Fernández JA, Liu D, et al: Activated protein C and ischemic stroke. Crit
Chem 265(14):8127–8135, 1990. Care Med 32(5 Suppl):S247–S253, 2004.
204. Saller F, Villoutreix BO, Amelot A, et al: The gamma-carboxyglutamic acid domain of 236. Guo H, Liu D, Gelbard H, et al: Activated protein C prevents neuronal apoptosis via
anticoagulant protein S is involved in activated protein C cofactor activity, indepen- protease activated receptors 1 and 3. Neuron 41(4):563–572, 2004.
dently of phospholipid binding. Blood 105(1):122–130, 2005. 237. Liu D, Cheng T, Guo H, et al: Tissue plasminogen activator neurovascular toxicity is
205. Saller F, Kaabache T, Aiach M, et al: The protein S thrombin-sensitive region modulates controlled by activated protein C. Nat Med 10(12):1379–1383, 2004.
phospholipid binding and the gamma-carboxyglutamic acid-rich (Gla) domain confor- 238. Shibata M, Kumar SR, Amar A, et al: Anti-inflammatory, antithrombotic, and neuro-
mation in a non-specific manner. J Thromb Haemost 4(3):704–706, 2006. protective effects of activated protein C in a murine model of focal ischemic stroke.
206. Heeb MJ, Mesters RM, Fernandez JA, et al: Plasma protein S residues 37–50 mediate Circulation 103(13):1799–1805, 2001.
its binding to factor Va and inhibition of blood coagulation. Thromb Haemost 110(2): 239. Wang Y, Zhang Z, Chow N, et al: An activated protein C analog with reduced anti-
275–282, 2013. coagulant activity extends the therapeutic window of tissue plasminogen activator for
207. Walker FJ: Regulation of vitamin K-dependent protein S. Inactivation by thrombin. ischemic stroke in rodents. Stroke 43(9):2444–2449, 2012.
J Biol Chem 259:10335–10339, 1984. 240. Wang Y, Zhao Z, Chow N, et al: Activated protein C analog promotes neurogenesis
208. Varadi K, Rosing J, Tans G, et al: Factor V enhances the cofactor function of protein S in and improves neurological outcome after focal ischemic stroke in mice via protease
the APC-mediated inactivation of factor VIII: Influence of the factor V R506Q mutation. activated receptor 1. Brain Res 1507:97–104, 2013.
Thromb Haemost 76(2):208–214, 1996. 241. Wang Y, Zhao Z, Chow N, et al: Activated protein C analog protects from ischemic
209. Thorelli E, Kaufman RJ, Dahlbäck B: Cleavage of factor V at Arg 506 by activated pro- stroke and extends the therapeutic window of tissue-type plasminogen activator in
tein C and the expression of anticoagulant activity of factor V. Blood 93(8):2552–2558, aged female mice and hypertensive rats. Stroke 44(12):3529–3536, 2013.
1999. 242. Zlokovic BV: Neurodegeneration and the neurovascular unit. Nat Med 16(12):1370–1371,
210. Cramer TJ, Gale AJ: The anticoagulant function of coagulation factor V. Thromb Hae- 2010.
most 107(1):15–21, 2012. 243. Petraglia AL, Marky AH, Walker C, et al: Activated protein C is neuroprotective and
211. Cramer TJ, Griffin JH, Gale AJ: Factor V Is an anticoagulant cofactor for activated mediates new blood vessel formation and neurogenesis after controlled cortical impact.
protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 37(1):17–23, Neurosurgery 66(1):165–171, 2010.
2010. 244. Thiyagarajan M, Fernandez JA, Lane SM, et al: Activated protein C promotes neovas-
212. Mineo C, Deguchi H, Griffin JH, Shaul PW: Endothelial and antithrombotic actions of cularization and neurogenesis in postischemic brain via protease-activated receptor 1.
HDL. Circ Res 98(11):1352–1364, 2006. J Neurosci 28(48):12788–12797, 2008.
213. Deguchi H, Pecheniuk NM, Elias DJ, et al: High-density lipoprotein deficiency and 245. Walker CT, Marky AH, Petraglia AL, et al: Activated protein C analog with reduced
dyslipoproteinemia associated with venous thrombosis in men. Circulation 112(6): anti-coagulant activity improves functional recovery and reduces bleeding risk follow-
893–899, 2005. ing controlled cortical impact. Brain Res 1347:125–131, 2010.
214. Eichinger S, Pecheniuk NM, Hron G, et al: High-density lipoprotein and the risk of 246. Lyden P, Levy H, Weymer S, et al: Phase 1 safety, tolerability and pharmacokinetics of
recurrent venous thromboembolism. Circulation 115(12):1609–1614, 2007. 3K3A-APC in healthy adult volunteers. Curr Pharm Des 19(42):7479–7485, 2013.
215. Deguchi H, Fernández JA, Pabinger I, et al: Plasma glucosylceramide deficiency as 247. Williams PD, Zlokovic BV, Griffin JH, et al: Preclinical safety and pharmacokinetic
potential risk factor for venous thrombosis and modulator of anticoagulant protein C profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr
pathway. Blood 97(7):1907–1914, 2001. Pharm Des 18(27):4215–4222, 2012.
216. Deguchi H, Fernández JA, Griffin JH: Neutral glycosphingolipid-dependent inac- 248. Mosnier LO, Griffin JH: Inhibition of staurosporine-induced apoptosis of endothelial
tivation of coagulation factor Va by activated protein C and protein S. J Biol Chem cells by activated protein C requires protease activated receptor-1 and endothelial cell
277(11):8861–8865, 2002. protein C receptor. Biochem J 373(Pt 1):65–70, 2003.
217. Yegneswaran S, Deguchi H, Griffin JH: Glucosylceramide, a neutral glycosphingolipid 249. Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C
anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood
C with negatively charged phospholipid vesicles. J Biol Chem 278(17):14614–14621, 2003. 105(8):3178–3184, 2005.

Kaushansky_chapter 114_p1949-1966.indd 1964 9/18/15 10:06 AM